Relmada Therapeutics Inc

$6.73
Market Cap 705.91M
ROE -71.2%
Gross Margin 0.0%
Debt/Equity 0.0
Current Ratio 18.3
Revenue QoQ 0.0%
EPS QoQ -0.6%
F-Score 3

About

Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS) and metabolic disorders. Relmada’s experienced and dedicated team is committed to making a difference in the lives of patients and their families.

Exchange
NASDAQ
Sector
Healthcare
Industry
Biotechnology

Sector context

Healthcare

Undervalued

Trading at a discount to sector peers

P/E
-11.85
vs median 32.28
P/B
3.19
vs median 2.77
ROE
-0.71
vs median 0.12

Lower quality - review fundamentals carefully

Small-cap company with higher volatility

Similar companies

Primary metric
Overlay metric
Loading chart data...
Fetching latest financial metrics